Speedy drug approvals have become the rule, not the exception

Congress has over the past few decades passed a series of special approval pathways for important drugs that treat life-threatening or rare diseases. This week, a new bill introduced in the House could add two more. Aaron Kesselheim, associate professor of medicine at Brigham and Women's Hospital, is quoted.

Read the full article